The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801).
D. E. Castellano
No relevant relationships to disclose
J. Capdevila
No relevant relationships to disclose
R. Salazar
No relevant relationships to disclose
J. Sastre
No relevant relationships to disclose
V. Alonso
No relevant relationships to disclose
M. Llanos
No relevant relationships to disclose
R. Garcia-Carbonero
No relevant relationships to disclose
A. Abad
No relevant relationships to disclose
I. Sevilla
No relevant relationships to disclose
I. Duran
No relevant relationships to disclose